Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of “Moderate Buy” from Brokerages

0
71
Revance Therapeutics logo


Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $37.90.

A number of brokerages have issued reports on RVNC. Mizuho lifted their price objective on Revance Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 9th. The Goldman Sachs Group began coverage on Revance Therapeutics in a research note on Thursday, September 22nd. They issued a “buy” rating and a $33.00 price target for the company. Guggenheim boosted their price target on Revance Therapeutics to $36.00 in a research note on Tuesday, November 15th. HC Wainwright boosted their price target on Revance Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, September 9th. Finally, StockNews.com cut Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 13th.

Institutional Trading of Revance Therapeutics

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in shares of Revance Therapeutics by 10.9% in the third quarter. California State Teachers Retirement System now owns 97,856 shares of the biopharmaceutical company’s stock worth $2,642,000 after acquiring an additional 9,642 shares during the period. Glenmede Trust Co. NA bought a new stake in Revance Therapeutics during the third quarter valued at about $300,000. Baird Financial Group Inc. bought a new stake in Revance Therapeutics during the third quarter valued at about $1,594,000. Kingsview Wealth Management LLC bought a new stake in Revance Therapeutics during the third quarter valued at about $243,000. Finally, Castleark Management LLC grew its holdings in Revance Therapeutics by 7.0% during the third quarter. Castleark Management LLC now owns 138,347 shares of the biopharmaceutical company’s stock valued at $3,735,000 after purchasing an additional 9,034 shares during the period. Institutional investors own 82.68% of the company’s stock.

Revance Therapeutics Stock Up 5.1 %

Shares of NASDAQ:RVNC opened at $19.71 on Friday. The stock has a fifty day simple moving average of $21.16 and a two-hundred day simple moving average of $21.03. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -5.03 and a beta of 0.57. Revance Therapeutics has a 12-month low of $11.27 and a 12-month high of $30.95. The company has a current ratio of 5.56, a quick ratio of 5.33 and a debt-to-equity ratio of 2.60.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.32). The company had revenue of $29.02 million for the quarter, compared to analysts’ expectations of $28.76 million. Revance Therapeutics had a negative net margin of 251.92% and a negative return on equity of 461.54%. On average, research analysts anticipate that Revance Therapeutics will post -4.38 earnings per share for the current fiscal year.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Further Reading

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Revance Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Revance Therapeutics wasn’t on the list.

While Revance Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover



Source link